Literature DB >> 35708873

Alcohol consumption, blood DNA methylation and breast cancer: a Mendelian randomisation study.

Xuan Zhou1,2, Lili Yu1,2, Lijuan Wang1,2, Jiarui Xiao1,2, Jing Sun1,2, Yajing Zhou1,2, Xiaolin Xu1,2, Wanghong Xu3, Athina Spiliopoulou4, Maria Timofeeva5, Xiaomeng Zhang6, Yazhou He7, Haomin Yang8,9, Harry Campbell6, Ben Zhang7, Yimin Zhu1,2, Evropi Theodoratou6, Xue Li10,11.   

Abstract

Alcohol intake is thought to be a risk factor for breast cancer, but the causal relationship and carcinogenic mechanisms are not clear. We performed an up-to-date meta-analysis of prospective studies to assess observational association, and then conducted MR analysis to make causal inference based on the genetic predisposition to alcohol consumption ("drinks per week") and pathological drinking behaviours ("alcohol use disorder" and "problematic alcohol use"), as well as genetically predicted DNA methylation at by alcohol-related CpG sites in blood. We found an observational dose-response association between alcohol intake and breast cancer incidence with an additional risk of 4% for per 10 g/day increase in alcohol consumption. Genetic predisposition to alcohol consumption ("drinks per week") was not causally associated with breast cancer incidence at the OR of 1.01 (95% CI 0.84, 1.23), but problematic alcohol use (PAU) was linked to a higher breast cancer risk at the OR of 1.76 (95% CI 1.04, 2.99) when conditioning on alcohol consumption. Epigenetic MR analysis identified four CpG sites, cg03260624 near CDC7 gene, cg10816169 near ZNF318 gene, cg03345232 near RIN3 gene, and cg26312998 near RP11-867G23.13 gene, where genetically predicted epigenetic modifications were associated with an increased breast cancer incidence risk. Our findings re-affirmed that alcohol consumption is of high risk for breast cancer incidence even at a very low dose, and the pathogenic effect of alcohol on breast cancer could be due to pathological drinking behaviour and epigenetic modification at several CpG sites, which could be potential intervention targets for breast cancer prevention.
© 2022. The Author(s).

Entities:  

Keywords:  Alcohol; Breast cancer; DNA methylation; Mendelian randomisation

Mesh:

Substances:

Year:  2022        PMID: 35708873      PMCID: PMC9329409          DOI: 10.1007/s10654-022-00886-1

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   12.434


  40 in total

1.  RIN3: a novel Rab5 GEF interacting with amphiphysin II involved in the early endocytic pathway.

Authors:  Hiroaki Kajiho; Kota Saito; Kyoko Tsujita; Kenji Kontani; Yasuhiro Araki; Hiroshi Kurosu; Toshiaki Katada
Journal:  J Cell Sci       Date:  2003-10-15       Impact factor: 5.285

2.  Alcohol Intake and Breast Cancer Risk in African American Women from the AMBER Consortium.

Authors:  Lindsay A Williams; Andrew F Olshan; Chi-Chen Hong; Elisa V Bandera; Lynn Rosenberg; Ting-Yuan David Cheng; Kathryn L Lunetta; Susan E McCann; Charles Poole; Laurence N Kolonel; Julie R Palmer; Christine B Ambrosone; Melissa A Troester
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-04-18       Impact factor: 4.254

Review 3.  Mendelian Randomization as an Approach to Assess Causality Using Observational Data.

Authors:  Peggy Sekula; Fabiola Del Greco M; Cristian Pattaro; Anna Köttgen
Journal:  J Am Soc Nephrol       Date:  2016-08-02       Impact factor: 10.121

Review 4.  Endosialin: molecular and functional links to tumor angiogenesis.

Authors:  S Kontsekova; K Polcicova; M Takacova; S Pastorekova
Journal:  Neoplasma       Date:  2016       Impact factor: 2.575

5.  Commonly studied single-nucleotide polymorphisms and breast cancer: results from the Breast Cancer Association Consortium.

Authors: 
Journal:  J Natl Cancer Inst       Date:  2006-10-04       Impact factor: 13.506

6.  A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma.

Authors:  Sandra P D'Angelo; Omid A Hamid; Ahmad Tarhini; Dirk Schadendorf; Bartosz Chmielowski; Frances A Collichio; Anna C Pavlick; Karl D Lewis; Susan C Weil; John Heyburn; Charles Schweizer; Daniel J O'Shannessy; Richard D Carvajal
Journal:  Invest New Drugs       Date:  2017-11-11       Impact factor: 3.651

7.  Cdc7 overexpression is an independent prognostic marker and a potential therapeutic target in colorectal cancer.

Authors:  Nathaniel Melling; Johanna Muth; Ronald Simon; Carsten Bokemeyer; Luigi Terracciano; Guido Sauter; Jakob Robert Izbicki; Andreas Holger Marx
Journal:  Diagn Pathol       Date:  2015-07-25       Impact factor: 2.644

8.  PhenoScanner: a database of human genotype-phenotype associations.

Authors:  James R Staley; James Blackshaw; Mihir A Kamat; Steve Ellis; Praveen Surendran; Benjamin B Sun; Dirk S Paul; Daniel Freitag; Stephen Burgess; John Danesh; Robin Young; Adam S Butterworth
Journal:  Bioinformatics       Date:  2016-06-17       Impact factor: 6.937

9.  The MR-Base platform supports systematic causal inference across the human phenome.

Authors:  Gibran Hemani; Jie Zheng; Benjamin Elsworth; Tom R Gaunt; Philip C Haycock; Kaitlin H Wade; Valeriia Haberland; Denis Baird; Charles Laurin; Stephen Burgess; Jack Bowden; Ryan Langdon; Vanessa Y Tan; James Yarmolinsky; Hashem A Shihab; Nicholas J Timpson; David M Evans; Caroline Relton; Richard M Martin; George Davey Smith
Journal:  Elife       Date:  2018-05-30       Impact factor: 8.140

Review 10.  Zinc-finger proteins in health and disease.

Authors:  Matteo Cassandri; Artem Smirnov; Flavia Novelli; Consuelo Pitolli; Massimiliano Agostini; Michal Malewicz; Gerry Melino; Giuseppe Raschellà
Journal:  Cell Death Discov       Date:  2017-11-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.